Abstract

Objective: To understand the essential structural features required for pancreatic lipase (PL) inhibitory activity and to design novel chemical entities, ligand-based pharmacophore modeling, virtual screening and docking studies were carried out.Methods: The pharmacophore model was generated based on 133 compounds with PL inhibitory activity using PHASE. An external test set and decoy dataset methods were applied to validate the hypothesis and to retrieve potential PL inhibitors. The generated hypothesis model was further subjected to virtual screening and molecular docking studies.Results: A five point pharmacophoric hypothesis model which consists of three hydrogen bond acceptor sites and two hydrophobic sites was developed. The generated pharmacophore gave significant 3D QSAR (three-dimensional Quantitative Structural Activity Relationship) model with r2 of 0.9389 and Q2 value of 0.4016. After database screening, five molecules were found to have better glide scores and binding interactions with the active site amino acid residues.Conclusion: As an outcome of this study, five hit molecules were suggested as potent PL inhibitors as they showed good glide scores as well as binding interactions with required active site amino acids. The five molecules obtained from this study may serve as potential leads for the development of promising anti-obesity agents.

Highlights

  • Obesity and excess weight are rapidly growing health hazards in the world

  • The primary goal of this study is to identify essential structural features that are responsible for potent pancreatic lipase (PL) inhibitory activity

  • Ligand-based pharmacophore modelling and atom based 3D QSAR were performed in PHASE module of Schrodinger

Read more

Summary

Introduction

Obesity and excess weight are rapidly growing health hazards in the world. The 2014 WHO report indicates that on the whole, about 13% of the world’s adult population (11% of men and 15% of women) are obese. There are very few options for the treatment of obesity. They are as follows: Cannabinoid receptor type 1 (CB1R) antagonist (rimonabant®), Anorectic agent (sibutramine, phentermine), and pancreatic lipase (PL) inhibitor orlistat. Anorectic agent sibutramine and phentermine were withdrawn due to cardiovascular issues and the potential for addiction respectively [3,4,5]. A pancreatic lipase inhibitor is the only peripherally acting FDA (Food and Drug Administration) approved the drug for obesity [6,7,8,9]. The pancreatic lipase inhibition results in the reduction of fat absorption and is beneficial for the regulation of metabolic disorders and obesity. PL inhibitors may devoid of side effects generally associated with other centrally acting antiobesity agents [7]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call